Bayer HealthCare and its development partner Janssen Pharmaceuticals, Inc. have initiated a clinical research program to explore the potential benefits of the oral Factor Xa inhibitor Xarelto (rivaroxaban) for the prevention and treatment of pulmonary embolism and deep vein thrombosis in patients with various types of cancer. Xarelto is an anticoagulant approved for seven indications for venous and arterial thromboembolic (VAT) conditions.

Rivaroxaban was discovered by Bayer HealthCare and is being jointly developed with Janssen Research & Development, LLC. Xarelto is marketed outside the US by Bayer HealthCare and in the US by Janssen Pharmaceuticals, Inc., a Johnson & Johnson Company). Xarelto is approved in more than 125 countries.

Source: Bayer HealthCare